Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relutrigine in Developmental and Epileptic Encephalopathies (EMERALD)
NCT07010471Phase 3Active, not recruiting
- Sponsor
- Praxis Precision Medicines
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of relutrigine in developmental and epileptic encephalopathy (DEE) (3 arms), sponsored by Praxis Precision Medicines. Primary endpoint: Effect of relutrigine on seizure frequency compared to placebo at 16 weeks. Started Jul 2025; status: active, not recruiting.
02
Drugs
relutrigine
03
Conditions
developmental and epileptic encephalopathy (DEE)
Beyond the preview
Go deeper on NCT07010471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07010471.